{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:34:37Z","timestamp":1790998477747,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two Chromatographic methods have been established and optimized for simultaneous determination of serdexmethylphenidate (SER.DMP) and dexmethylphenidate (DMP) in the presence of their degradation products. The first method is a reversed phase high performance liquid chromatography with diode array detection (HPLC\u2013DAD). Isocratic separation was carried out on Waters X-bridge Shield RP<jats:sub>18<\/jats:sub> column (150\u00d73.9\u00d75\u00a0\u03bcm particle size) using a mixture of 5\u00a0mM phosphate buffer (pH 5.5): acetonitrile (40:60, v\/v) as a mobile phase, flow rate 1\u00a0mL\/min and detection at 220\u00a0nm. The second method is a thin-layer chromatography (TLC)\u2014densitometry method using methanol: chloroform (70:30, v\/v) as a mobile phase and UV scanning at 220\u00a0nm. In HPLC method, the linearity range of SER.DMP was (2.5\u201325\u00a0\u03bcg\/mL); with LOD (0.051\u00a0\u03bcg\/mL) and LOQ (0.165\u00a0\u03bcg\/mL) while for DMP was (2.5\u201325\u00a0\u03bcg\/mL); with LOD and LOQ of (0.098\u00a0\u03bcg\/mL) and (0.186\u00a0\u03bcg\/mL), respectively. For TLC method the sensitivity range of SER.DMP was (5\u201325\u00a0\u03bcg\/mL), LOD was (0.184\u00a0\u03bcg\/spot), while LOQ was (0.202\u00a0\u03bcg\/ spot) whereas for DMP the sensitivity range was (5\u201325\u00a0\u03bcg\/mL) with LOD of (0.115\u00a0\u03bcg\/ spot) and LOQ of (0.237\u00a0\u03bcg\/ spot), respectively. SER.DMP was found to be equally labile to acidic and alkaline hydrolysis, whereas DMP was sensitive to acidic hydrolysis only. Both drugs were successfully determined in presence of acidic and basic degradants by the two developed methods (stability indicating assay method). Chromatographic separation of the degradation products was carried out on TLC aluminum silica plates 60 F254, as a stationary phase, using methanol: dichloroethane: acetonitrile (60:20:20 v\/v), as a mobile phase. The degradation pathway was confirmed using TLC, IR, <jats:sup>1<\/jats:sup>H-NMR and mass spectroscopy; moreover, the separation power was correlated to the computational results by applying molecular dynamic simulation. The developed methods were validated according to the International Conference on Harmonization (ICH) guidelines demonstrating good accuracy and precision. They were successfully applied for quantitation of SER.DMP and DMP in pure and capsule forms. The results were statistically compared with those obtained by the reported method in terms of accuracy, precision and robustness, and no significant difference was found.<\/jats:p>","DOI":"10.1186\/s13065-023-00986-3","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T05:01:47Z","timestamp":1689397307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chromatographic reversed HPLC and TLC-densitometry methods for simultaneous determination of serdexmethylphenidate and dexmethylphenidate in presence of their degradation products\u2014with computational assessment"],"prefix":"10.1186","volume":"17","author":[{"given":"Khadiga M.","family":"Kelani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M. W.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal A.","family":"Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Morshedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elsonbaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"986_CR1","volume-title":"Martindale: the complete drug reference","author":"S Sweetman","year":"2009","unstructured":"Sweetman S. Martindale: the complete drug reference. 36th ed. London: The Pharmaceutical Press; 2009.","edition":"36"},{"key":"986_CR2","unstructured":"Pharmacopeia U.S. National Formulary 35, United States Pharmacopeia Convention Inc. 30th edn, 2012\u20132015."},{"key":"986_CR3","unstructured":"Center for Drug Evaluation and Research. Drug approval package: AZSTARYS (serdexmethylphenidate and dexmethylphenidate).\u00a0Silver Spring (MD):\u00a0FDA;\u00a02021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/212994Orig1s000TOC.cfm. Accessed from 18 Nov 2021."},{"issue":"7","key":"986_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/03007995.2022.2076474","volume":"38","author":"MJ Shram","year":"2022","unstructured":"Shram MJ, Setnik B, Webster L, Guenther S, Mickle TC, Braeckman R, Kanski J, Martin A, Kelsh D, Vince BD, Barrett AC. Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate. Curr Med Res Opin. 2022;38(7):1237\u201350. https:\/\/doi.org\/10.1080\/03007995.2022.2076474.","journal-title":"Curr Med Res Opin"},{"key":"986_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmac011","author":"G Gollu","year":"2022","unstructured":"Gollu G, Gummadi S. A novel stability indicating rp-hplc method for simultaneous quantification of serdexmethylphenidate and dexmethylphenidate in fixed dosage form. J Chromatograp Sci. 2022. https:\/\/doi.org\/10.1093\/chromsci\/bmac011.","journal-title":"J Chromatograp Sci"},{"issue":"31","key":"986_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.9734\/jpri\/2021\/v33i31B31707","volume":"33","author":"S Talari","year":"2021","unstructured":"Talari S, Anuradha V, Boddapati MSN, Ayithabotla KSP. A newly developed reverse phase-high performance liquid chromatography method for the assay of dexmethylphenidate and serdexmethylphenidate with PDA. J Pharma Res Int. 2021;33(31):203\u201311.","journal-title":"J Pharma Res Int"},{"issue":"2","key":"986_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2215\/ijap.2022v14i2.43515","volume":"14","author":"S Rayudu","year":"2022","unstructured":"Rayudu S, Manoranjani M, Reddy RS. Analytical method development and validation of dexmethylphenidate and serdexmethylphenidate by using RP-HPLC in bulk and pharmaceutical dosage form. Int J Appl Pharmac. 2022;14(2):110\u20135. https:\/\/doi.org\/10.2215\/ijap.2022v14i2.43515.","journal-title":"Int J Appl Pharmac"},{"key":"986_CR8","doi-asserted-by":"publisher","DOI":"10.1149\/1945-7111\/abff65","author":"A Elsonbaty","year":"2021","unstructured":"Elsonbaty A, Attala K. Application of experimental design approaches and in silico molecular docking on the host-guest complexes with cyclodextrins for the analysis of benazepril hydrochloride in pharmaceutical formulation. J Electrochem Soc. 2021. https:\/\/doi.org\/10.1149\/1945-7111\/abff65.","journal-title":"J Electrochem Soc"},{"issue":"1","key":"986_CR9","first-page":"141","volume":"7","author":"MW Nassar","year":"2018","unstructured":"Nassar MW, Attia KAM, Said RA, El-Olemy A, Hasan MA. Stability indicating HPLC-DAD and TLC densitometric methods for the determination of crotamiton in the presence of its degradation products. World J Pharm Pharm Sci. 2018;7(1):141\u201359.","journal-title":"World J Pharm Pharm Sci"},{"key":"986_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13065-022-00906-x","volume":"16","author":"KM Kelani","year":"2022","unstructured":"Kelani KM, Nassar AMW, Omran GA, Morshedy S, Talaat W. Comparative Study of extension area based methods for spectrophotometric determination of desmopressin acetate in the presence of its acid-induced degradation products. BMC Chem. 2022;16:117. https:\/\/doi.org\/10.1186\/s13065-022-00906-x.","journal-title":"BMC Chem"},{"issue":"4","key":"986_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jaoac\/93.4.1180","volume":"93","author":"LS Abdel Fattah","year":"2010","unstructured":"Abdel Fattah LS, ElSherif ZA, Kelani KM, El-Haddad DA. HPLC, TLC, and first-derivative spectrophotometry stability indicating methods for the determination of tropisetron in the presence of its acid degradates. J AOAC Int. 2010;93(4):1180\u201391.","journal-title":"J AOAC Int"},{"key":"986_CR12","unstructured":"International Conference on Harmonization, ICH Harmonized Tripartite Guidelines. Validation of analytical procedure: text and methodology, Q2 (R1). Geneva: International Conference on Harmonization; 2005."},{"key":"986_CR13","unstructured":"International Conference on Harmonization (ICH) guidelines. Stability testing on new drug substances and products\u201d (ICH (2003) Stability Testing of New Drug Substances and Products, Q1AR2, International Conference on Harmonization, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland."},{"key":"986_CR14","first-page":"1","volume":"24","author":"S Singh","year":"2000","unstructured":"Singh S, Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm Tech Online. 2000;24:1\u201314.","journal-title":"Pharm Tech Online"},{"key":"986_CR15","first-page":"48","volume":"26","author":"DW Reynolds","year":"2002","unstructured":"Reynolds DW, Fachine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Available guidance and best practices for conducting forced degradation studies. Pharm Technol. 2002;26:48\u201356.","journal-title":"Pharm Technol"},{"key":"986_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0731-7085(02)00047-X","volume":"28","author":"M Bakshi","year":"2002","unstructured":"Bakshi M, Singh S. Development of validated stability-indicating assay methods\u2014critical review. J Pharm Biomed Anal. 2002;28:1011\u201340.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"986_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs\u2014a review. J Pharm Anal. 2014;4(3):159\u201365.","journal-title":"J Pharm Anal"},{"key":"986_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13065-023-00931-4","volume":"17","author":"KM Kelani","year":"2023","unstructured":"Kelani KM, Emara MS, Madkour AW, Batakoushy HA, Tony RM. The simultaneous measurement of quaternary mixture in over-the-counter cold medications using sequential spectrophotometric resolution approach enhanced with in-lab sample enrichment. BMC Chemistry. 2023;17:24. https:\/\/doi.org\/10.1186\/s13065-023-00931-4.","journal-title":"BMC Chemistry"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-023-00986-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-023-00986-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-023-00986-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T05:03:38Z","timestamp":1689397418000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-023-00986-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1186\/s13065-023-00986-3","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}